258 related articles for article (PubMed ID: 22037582)
1. Crystal structure of human prostate-specific antigen in a sandwich antibody complex.
Stura EA; Muller BH; Bossus M; Michel S; Jolivet-Reynaud C; Ducancel F
J Mol Biol; 2011 Dec; 414(4):530-44. PubMed ID: 22037582
[TBL] [Abstract][Full Text] [Related]
2. Selective recognition of enzymatically active prostate-specific antigen (PSA) by anti-PSA monoclonal antibodies.
Michel S; Collomb-Clerc E; Geourjon C; Charrier JP; Passagot J; Courty Y; Deléage G; Jolivet-Reynaud C
J Mol Recognit; 2005; 18(3):225-35. PubMed ID: 15593306
[TBL] [Abstract][Full Text] [Related]
3. In vitro affinity maturation of an anti-PSA antibody for prostate cancer diagnostic assay.
Muller BH; Savatier A; L'Hostis G; Costa N; Bossus M; Michel S; Ott C; Becquart L; Ruffion A; Stura EA; Ducancel F
J Mol Biol; 2011 Dec; 414(4):545-62. PubMed ID: 22019475
[TBL] [Abstract][Full Text] [Related]
4. Crystal structure of a ternary complex between human prostate-specific antigen, its substrate acyl intermediate and an activating antibody.
Ménez R; Michel S; Muller BH; Bossus M; Ducancel F; Jolivet-Reynaud C; Stura EA
J Mol Biol; 2008 Feb; 376(4):1021-33. PubMed ID: 18187150
[TBL] [Abstract][Full Text] [Related]
5. Different glycan structures in prostate-specific antigen from prostate cancer sera in relation to seminal plasma PSA.
Tabarés G; Radcliffe CM; Barrabés S; Ramírez M; Aleixandre RN; Hoesel W; Dwek RA; Rudd PM; Peracaula R; de Llorens R
Glycobiology; 2006 Feb; 16(2):132-45. PubMed ID: 16177264
[TBL] [Abstract][Full Text] [Related]
6. Oligosaccharide profiles of the prostate specific antigen in free and complexed forms from the prostate cancer patient serum and in seminal plasma: a glycopeptide approach.
Tajiri M; Ohyama C; Wada Y
Glycobiology; 2008 Jan; 18(1):2-8. PubMed ID: 17956937
[TBL] [Abstract][Full Text] [Related]
7. Carbohydrate structure and differential binding of prostate specific antigen to Maackia amurensis lectin between prostate cancer and benign prostate hypertrophy.
Ohyama C; Hosono M; Nitta K; Oh-eda M; Yoshikawa K; Habuchi T; Arai Y; Fukuda M
Glycobiology; 2004 Aug; 14(8):671-9. PubMed ID: 15044396
[TBL] [Abstract][Full Text] [Related]
8. Characterization of prostate-specific antigen binding peptides selected by phage display technology.
Ferrieu-Weisbuch C; Michel S; Collomb-Clerc E; Pothion C; Deléage G; Jolivet-Reynaud C
J Mol Recognit; 2006; 19(1):10-20. PubMed ID: 16312021
[TBL] [Abstract][Full Text] [Related]
9. The importance of human glandular kallikrein and its correlation with different prostate specific antigen serum forms in the detection of prostate carcinoma.
Recker F; Kwiatkowski MK; Piironen T; Pettersson K; Lümmen G; Wernli M; Wiefelspütz J; Graber SF; Goepel M; Huber A; Tscholl R
Cancer; 1998 Dec; 83(12):2540-7. PubMed ID: 9874461
[TBL] [Abstract][Full Text] [Related]
10. Differential percentage of serum prostate-specific antigen subforms suggests a new way to improve prostate cancer diagnosis.
Sarrats A; Comet J; Tabarés G; Ramírez M; Aleixandre RN; de Llorens R; Peracaula R
Prostate; 2010 Jan; 70(1):1-9. PubMed ID: 19670261
[TBL] [Abstract][Full Text] [Related]
11. Altered glycosylation pattern allows the distinction between prostate-specific antigen (PSA) from normal and tumor origins.
Peracaula R; Tabarés G; Royle L; Harvey DJ; Dwek RA; Rudd PM; de Llorens R
Glycobiology; 2003 Jun; 13(6):457-70. PubMed ID: 12626390
[TBL] [Abstract][Full Text] [Related]
12. Glycan characterization of PSA 2-DE subforms from serum and seminal plasma.
Sarrats A; Saldova R; Comet J; O'Donoghue N; de Llorens R; Rudd PM; Peracaula R
OMICS; 2010 Aug; 14(4):465-74. PubMed ID: 20726802
[TBL] [Abstract][Full Text] [Related]
13. Screening for prostate cancer in 2008 II: the importance of molecular subforms of prostate-specific antigen and tissue kallikreins.
Jansen FH; Roobol M; Jenster G; Schröder FH; Bangma CH
Eur Urol; 2009 Mar; 55(3):563-74. PubMed ID: 19058905
[TBL] [Abstract][Full Text] [Related]
14. alpha1,2-Fucosylated and beta-N-acetylgalactosaminylated prostate-specific antigen as an efficient marker of prostatic cancer.
Fukushima K; Satoh T; Baba S; Yamashita K
Glycobiology; 2010 Jan; 20(4):452-60. PubMed ID: 20008118
[TBL] [Abstract][Full Text] [Related]
15. Characterization and determination of the complex between prostate-specific antigen and alpha 1-protease inhibitor in benign and malignant prostatic diseases.
Zhang WM; Finne P; Leinonen J; Stenman UH
Scand J Clin Lab Invest Suppl; 2000; 233():51-8. PubMed ID: 11317942
[TBL] [Abstract][Full Text] [Related]
16. A structural model for the prostate disease marker, human prostate-specific antigen.
Villoutreix BO; Getzoff ED; Griffin JH
Protein Sci; 1994 Nov; 3(11):2033-44. PubMed ID: 7535613
[TBL] [Abstract][Full Text] [Related]
17. Two-dimensional electrophoresis of prostate-specific antigen in sera of men with prostate cancer or benign prostate hyperplasia.
Charrier JP; Tournel C; Michel S; Dalbon P; Jolivet M
Electrophoresis; 1999; 20(4-5):1075-81. PubMed ID: 10344287
[TBL] [Abstract][Full Text] [Related]
18. Purification of human prostatic-specific antigen (hPSA) from seminal plasma by immunoaffinity chromatography using a monoclonal antibody anti total PSA.
Pérez L; Zulueta O; Melchor A; Hernández L; López R; Cazanave J; Béquer D
Hybridoma (Larchmt); 2011 Jun; 30(3):247-51. PubMed ID: 21707359
[TBL] [Abstract][Full Text] [Related]
19. A truncated precursor form of prostate-specific antigen is a more specific serum marker of prostate cancer.
Mikolajczyk SD; Marker KM; Millar LS; Kumar A; Saedi MS; Payne JK; Evans CL; Gasior CL; Linton HJ; Carpenter P; Rittenhouse HG
Cancer Res; 2001 Sep; 61(18):6958-63. PubMed ID: 11559576
[TBL] [Abstract][Full Text] [Related]
20. Cross-reactivity of ten anti-prostate-specific antigen monoclonal antibodies with human glandular kallikrein.
Corey E; Buhler KR; Vessella RL
Urology; 1997 Oct; 50(4):567-71; discussion 571-2. PubMed ID: 9338733
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
